West Pharmaceutical Services (WPS) Stock Statistics & Valuation Metrics

West Pharmaceutical Services has a market cap or net worth of CHF 23.68B. The enterprise value is CHF 26.10B.

Market Cap

CHF 23.68B

Enterprise Value

CHF 26.10B

West Pharmaceutical Services has 69,661,030 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

69,661,030

Owned by Insiders

0.55%

Owned by Institutions

61.87%

West Pharmaceutical Services’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 13.62%.

Return on Equity (ROE)

0.16

Return on Assets (ROA)

0.12

Return on Invested Capital (ROIC)

13.62%

Return on Capital Employed (ROCE)

0.17

Revenue Per Employee

284.60K

Profits Per Employee

45.71K

Employee Count

10,800

Asset Turnover

0.72

Inventory Turnover

4.44

The current PE Ratio of West Pharmaceutical Services is 46.00. West Pharmaceutical Services’s PEG ratio is 1.43.

PE Ratio

46.00

PS Ratio

8.46

PB Ratio

9.79

Price to FCF

63.40

Price to Operating Cash Flow

44.38

PEG Ratio

1.43

In the last 12 months, West Pharmaceutical Services had revenue of 3.07B and earned 493.70M in profits. Earnings per share was 6.83.

Revenue

3.07B

Gross Profit

1.10B

Operating Income

617.40M

Pretax Income

615.30M

Net Income

493.70M

EBITDA

770.60M

Earnings Per Share (EPS)

6.83

In the last 12 months, operating cash flow was 654.50M and capital expenditures -201.10M, giving a free cash flow of 453.40M billion.

Operating Cash Flow

654.50M

Free Cash Flow

453.40M

Free Cash Flow per Share

6.44

West Pharmaceutical Services pays an annual dividend of ―, resulting in a dividend yield of 0.21%

Dividend Per Share

―

Dividend Yield

0.21%

Payout Ratio

N/A

Free Cash Flow Yield

1.58%

Earnings Yield

2.20%

Beta

0.99

52-Week Price Change

―

50-Day Moving Average

―

200-Day Moving Average

―

Relative Strength Index (RSI)

―

Average Volume (3m)

―

West Pharmaceutical Services upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Feb 18, 2027

Ex-Dividend Date

―

West Pharmaceutical Services as a current ratio of 3.02, with Debt / Equity ratio of 13.12%

Current Ratio

3.02

Quick Ratio

2.34

Debt to Market Cap

0.02

Net Debt to EBITDA

-0.49

Interest Coverage Ratio

1029.00

In the past 12 months, West Pharmaceutical Services has paid 121.60M in taxes.

Income Tax

121.60M

Effective Tax Rate

0.20

West Pharmaceutical Services EV to EBITDA ratio is 29.56, with an EV/FCF ratio of 63.04.

EV to Sales

8.42

EV to EBITDA

29.56

EV to Free Cash Flow

63.04

EV to Operating Cash Flow

43.67

West Pharmaceutical Services has CHF 464.10M in cash and marketable securities with CHF 305.00M in debt, giving a net cash position of CHF 159.10M billion.

Cash & Marketable Securities

CHF 464.10M

Total Debt

CHF 305.00M

Net Cash

CHF 159.10M

Net Cash Per Share

CHF 2.28

Tangible Book Value Per Share

CHF 40.53

Gross margin is 37.59%, with operating margin of 22.97%, and net profit margin of 18.81%.

Gross Margin

37.59%

Operating Margin

22.97%

Pretax Margin

23.36%

Net Profit Margin

18.81%

EBITDA Margin

28.47%

EBIT Margin

23.06%

The average price target for West Pharmaceutical Services is CHF 392.44, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

CHF 392.44

Price Target Upside

―

Analyst Consensus

Strong Buy

Analyst Count

6

Revenue Growth Forecast

5.63%

EPS Growth Forecast

24.62%

Smart Score

7

AI Score

―